Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-121 + tezacaftor + deutivacaftor versus elexacaftor + tezacaftor + ivacaftor in cystic fibrosis
MOH_2022-03-01_010646Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Elexacaftor + tezacaftor + ivacaftor control arm with VX-121 + tezacaftor + deutivacaftor investigational arm (2 arms). Started Feb 2022; status: completed.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2022-03-01_010646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-01_010646.